137 related articles for article (PubMed ID: 15806151)
21. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.
Holm C; Kok M; Michalides R; Fles R; Koornstra RH; Wesseling J; Hauptmann M; Neefjes J; Peterse JL; Stål O; Landberg G; Linn SC
J Pathol; 2009 Feb; 217(3):372-9. PubMed ID: 18991335
[TBL] [Abstract][Full Text] [Related]
22. Coordinated expression of Ets-1, pERK1/2, and VEGF in retina of streptozotocin-induced diabetic rats.
Du ZJ; Kamei M; Suzuki M; Tano Y; Wang BR; Hui YN
Ophthalmic Res; 2007; 39(4):224-31. PubMed ID: 17622743
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
24. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
25. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
Schmitz KJ; Wohlschlaeger J; Lang H; Sotiropoulos GC; Malago M; Steveling K; Reis H; Cicinnati VR; Schmid KW; Baba HA
J Hepatol; 2008 Jan; 48(1):83-90. PubMed ID: 17998146
[TBL] [Abstract][Full Text] [Related]
26. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen].
Antunes A; Silva T; Godinho I; Amaral N; Oliveira C
Acta Med Port; 2004; 17(4):271-6. PubMed ID: 15941551
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
30. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
31. STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell.
Jung HH; Lee J; Kim JH; Ryu KJ; Kang SA; Park C; Sung K; Nam DH; Kang WK; Park K; Im YH
FEBS Lett; 2005 Jul; 579(18):3941-6. PubMed ID: 15996661
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.
Sarwar N; Kim JS; Jiang J; Peston D; Sinnett HD; Madden P; Gee JM; Nicholson RI; Lykkesfeldt AE; Shousha S; Coombes RC; Ali S
Endocr Relat Cancer; 2006 Sep; 13(3):851-61. PubMed ID: 16954434
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
35. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
[TBL] [Abstract][Full Text] [Related]
36. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
Ushio K; Hashimoto T; Kitamura N; Tanaka T
Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
[TBL] [Abstract][Full Text] [Related]
37. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.
Giatromanolaki A; Koukourakis MI; Sivridis E; Chlouverakis G; Vourvouhaki E; Turley H; Harris AL; Gatter KC
Eur J Clin Invest; 2007 Nov; 37(11):878-86. PubMed ID: 17883421
[TBL] [Abstract][Full Text] [Related]
38. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
Rayala SK; Kumar R
Biomed Pharmacother; 2007 Aug; 61(7):408-11. PubMed ID: 17604944
[TBL] [Abstract][Full Text] [Related]
39. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer.
Al-azawi D; Ilroy MM; Kelly G; Redmond AM; Bane FT; Cocchiglia S; Hill AD; Young LS
Oncogene; 2008 May; 27(21):3021-31. PubMed ID: 18059336
[TBL] [Abstract][Full Text] [Related]
40. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
